Lake Bluff, IL, United States of America

Jun Chen


Average Co-Inventor Count = 6.4

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2013-2017

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovator Jun Chen: Pioneering TRPA1 Antagonists in Pharmaceutical Research

Introduction

Jun Chen, an accomplished inventor based in Lake Bluff, Illinois, has made significant contributions to the field of pharmaceutical research. With a total of five patents to his name, his work primarily focuses on TRPA1 antagonists, which have promising applications in treating various medical conditions and disorders.

Latest Patents

Among Jun Chen's latest patents are groundbreaking formulations of TRPA1 antagonists. These compounds, described in patents where R, R, R, and Y are defined, target the TRPA1 receptor and open new avenues for therapeutic interventions. His research includes innovative compositions comprised of these compounds and outlines methods for effectively treating diseases associated with TRPA1 modulation. Additionally, another patent features similar compounds with variations defined in the specification, highlighting his extensive work on TRPA1 antagonists and their medicinal benefits.

Career Highlights

Currently, Jun Chen is affiliated with AbbVie Inc., a global biopharmaceutical company dedicated to addressing complex health challenges through advanced science and research. His tenure at AbbVie has been marked by a commitment to exploring novel therapeutic strategies, particularly in the realm of pain and sensory disorders linked to TRPA1 receptors.

Collaborations

Throughout his career, Jun Chen has collaborated with fellow researchers and inventors, including Richard J. Perner and Michael E. Kort. These partnerships enhance the depth of his research, fostering an environment for innovation and the development of transformative solutions in the pharmaceutical landscape.

Conclusion

Jun Chen exemplifies the spirit of innovation within the biopharmaceutical industry. His focused research on TRPA1 antagonists not only underscores his expertise as an inventor but also contributes to the broader field of medical science. As he continues his work at AbbVie Inc., his discoveries have the potential to significantly impact patient care and therapeutic outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…